A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/29/2011	US20110318432 Compositions for the treatment of gastro-esofageal reflux disease (gerd)
12/29/2011	US20110318431 Pharmaceutical Compositions and Methods of Treating Neurological Insults
12/29/2011	US20110318430 Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
12/29/2011	US20110318429 Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum
12/29/2011	US20110318422 Targeted active agent delivery system based on calcium phosphate nanoparticles
12/29/2011	US20110318421 Surface functionalized ceramic nanoparticles
12/29/2011	US20110318420 Fulvestrant nanosphere/microsphere and preparative method and use thereof
12/29/2011	US20110318416 Bioresorbable polymer matrices and methods of making and using the same
12/29/2011	US20110318409 Fractions of wheat germ ferment
12/29/2011	US20110318401 Treatment of leg ulcers using placenta derived collagen biofabric
12/29/2011	US20110318393 Substituted Pyrazole Compounds
12/29/2011	US20110318388 S1P Receptors Modulators and Their Use Thereof
12/29/2011	US20110318384 Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant lactobacillus transformed by the same
12/29/2011	US20110318380 MHC Multimers in Cancer Vaccines and Immune Monitoring
12/29/2011	US20110318374 Spanx-b polypeptides and their use
12/29/2011	US20110318373 Immunosuppression modulating compounds
12/29/2011	US20110318372 Indoleamine 2,3-dioxygenase based immunotherapy
12/29/2011	US20110318371 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
12/29/2011	US20110318370 Cxcl4l1 as a biomarker of pancreatic cancer
12/29/2011	US20110318369 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
12/29/2011	US20110318368 Anti-human alpha9 integrin antibody and use thereof
12/29/2011	US20110318366 Biologic compounds
12/29/2011	US20110318364 nonapeptide with anti-tumour activity
12/29/2011	US20110318362 Novel card proteins involved in cell death regulation
12/29/2011	US20110318361 Anticancer Drug Comprising Inhibitor of Tmprss4
12/29/2011	US20110318355 Mutant proteins of the f protein of piv-5 and piv-2
12/29/2011	US20110318351 Novel methods of cancer diagnosis and therapy targeted against a cancer stem line
12/29/2011	US20110318349 Dual variable domain immunoglobulins and uses thereof
12/29/2011	US20110318345 Nasal delivery
12/29/2011	US20110318341 Frizzled-binding agents and uses thereof
12/29/2011	US20110318340 Deglycosylated antibodies
12/29/2011	US20110318339 Anti-dll4 antibodies and uses thereof
12/29/2011	US20110318338 Targeting pax2 for the treatment of breast cancer
12/29/2011	US20110318336 Identification and Treatment of Aggressive Lung Cancer Tumors
12/29/2011	US20110318335 Methods and products for treating proliferative diseases
12/29/2011	US20110318334 Taxane analogs for the treatment of brain cancer
12/29/2011	US20110318318 Anti-apoptotic fusion proteins
12/29/2011	US20110318311 Tumor-selective e1a and e1b mutants
12/29/2011	US20110318309 Equol-producing bacterium and use thereof
12/29/2011	US20110318308 Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis
12/29/2011	US20110318306 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
12/29/2011	US20110318304 Detection of epha3 as a marker of the presence of a solid tumor
12/29/2011	US20110318302 Cancer Treatment
12/29/2011	US20110318275 Multifunctional contrast agent using biocompatible polymer and preparation method
12/29/2011	US20110318267 Ph-responsive nanostructures
12/29/2011	US20110318265 Coupled identification and treatment of cancer
12/29/2011	US20110318264 Methods and compositions for diagnosis and treatment of cancer
12/29/2011	US20110315575 Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of Cancers
12/29/2011	DE102010032149A1 Nano-Hydrogele für die therapeutische und nichttherapeutische Behandlung, insbesondere zur Therapie von Stresszuständen und Regeneration geschädigter Zellsysteme (Nano-Shuttle-System) Nano-hydrogels for the therapeutic and non-therapeutic treatment, in particular for the treatment of stress conditions and regeneration of damaged cell systems (nano-shuttle system)
12/29/2011	DE102010030538A1 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln 6,7-dihydro-5H-benzo [7] annulene derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use for the preparation of medicaments
12/29/2011	DE102010025173A1 Verwendung von Dibenzofuranonderivaten zur Inhibierung von Kinasen Use of Dibenzofuranonderivaten for inhibiting kinases
12/29/2011	CA2803913A1 Tumor growth controlling method targeting galactosylceramide expression factor-1
12/29/2011	CA2803802A1 Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
12/29/2011	CA2803697A1 Beta carboline derivatives useful in the treatment of proliferative disorders
12/29/2011	CA2803559A1 Nilotinib salts and crystalline forms thereof
12/29/2011	CA2803391A1 Colon and pancreas cancer specific antigens and antibodies
12/29/2011	CA2803058A1 Homodimeric protein constructs
12/29/2011	CA2803056A1 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
12/29/2011	CA2803055A1 Heteroaryl compounds and compositions as protein kinase inhibitors
12/29/2011	CA2803027A1 Treatment of proliferative diseases
12/29/2011	CA2802895A1 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
12/29/2011	CA2802644A1 Antitumor agent using compounds having kinase inhibitory effect in combination
12/29/2011	CA2802209A1 Sustained-release formulation
12/29/2011	CA2796192A1 Polymorphs of osi-906
12/29/2011	CA2788398A1 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
12/28/2011	EP2400021A2 ErbB3 based methods and compositions for treating neoplasms
12/28/2011	EP2399937A1 Anti-human alpha9 integrin antibody and use thereof
12/28/2011	EP2399930A1 N-terminally monopegylated polypeptides and process for their preparation
12/28/2011	EP2399921A1 Heterocyclic compound and use thereof
12/28/2011	EP2399909A1 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors
12/28/2011	EP2399908A1 Polymorphic form of 7-ethyl-10[4-(1-piperidino)-1- piperidino]carbonyloxy- camptothecin and its use
12/28/2011	EP2399900A1 Geranyl compounds
12/28/2011	EP2399899A1 Geranyl compounds
12/28/2011	EP2399611A2 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metasatases in cancer treatment
12/28/2011	EP2399605A1 Extending time to disease progression or survival in cancer patients
12/28/2011	EP2399598A1 Blockade of CCL18 signaling via CCR6 as a therapeutic option in fibrotic diseases and cancer
12/28/2011	EP2399582A1 Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
12/28/2011	EP2399573A1 Compositions comprising poorly water soluble pharmaceutical agents
12/28/2011	EP2399571A1 Therapeutic compositions comprising ingenol-3-angelate
12/28/2011	EP2398901A1 Jarid1b for target gene of cancer therapy and diagnosis
12/28/2011	EP2398828A2 Specific binding proteins and uses thereof
12/28/2011	EP2398820A2 Cancer-targeting peptides and uses thereof in cancer therapy
12/28/2011	EP2398807A1 (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
12/28/2011	EP2398806A1 (+)-morphinanium n-oxides and processes for their production
12/28/2011	EP2398805A1 (+)-morphinanium quaternary salts and processes for their production
12/28/2011	EP2398801A1 3, 3' -spiroindolinone derivatives as anticancer agents
12/28/2011	EP2398799A2 Pyridocarbazole type compounds and applications thereof
12/28/2011	EP2398797A1 Pyrimido [5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
12/28/2011	EP2398791A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
12/28/2011	EP2398790A1 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
12/28/2011	EP2398783A1 Carboxamide compounds and their use as calpain inhibitors
12/28/2011	EP2398560A1 Methods for treating lipomas and liposarcomas
12/28/2011	EP2398504A1 Methods and kits for diagnosis of cancer and prediction of therapeutic value
12/28/2011	EP2398500A2 Glutathione-based drug delivery system
12/28/2011	EP2398494A2 Proproteins and methods of use thereof
12/28/2011	EP2398486A1 Compositions and methods to prevent and/or treat cancer with pa -card
12/28/2011	EP2398484A1 Inhibition of multiple cell activation pathways
12/28/2011	EP2398482A2 Methods and compositions for inhibiting cellular proliferation and surgical adhesion
12/28/2011	EP2398466A2 Methods and compositions for localized agent delivery
12/28/2011	EP2154971B1 A synergistic pharmaceutical combination for the treatment of cancer

1 ... 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 ... 2211